Patients HCPs
This site is for US health care professionals only.
About BRAF+ Melanoma

About BRAF+ Melanoma

BRAF Mutations in Melanoma

TAKE EVERY ADVANTAGE IN THE TREATMENT OF BRAF+ MELANOMA

EARLY ACTION IS THE FIRST STEP IN PLANNING FOR LONG-TERM SUCCESS

  • About 50% of patients with melanoma harbor BRAF mutations1

PATIENTS WITH STAGE III BRAF+ MELANOMA ARE HIGHLY SUSCEPTIBLE TO RELAPSE

Relapse rate 3 years after surgery without adjuvant therapy2

54% relapse rate in BRAF wild-type melanoma and 77% relapse rate in BRAF+ melanoma

PUT PATIENTS WHO ARE BRAF+ ON THE PATH TO RELAPSE-FREE SURVIVAL WITH TAFINLAR + MEKINIST TREATMENT IMMEDIATELY FOLLOWING SURGERY

PATIENTS WITH BRAF+ MELANOMA HAVE A HIGHER RISK OF MORTALITY
Median OS from diagnosis of first distant metastasis3,a

Median overall survival from diagnosis of first distant metastasis
BRAF WT vs BRAF mutant median overall survival

OS, overall survival; WT, wild type.
aProspective cohort study of consecutive patients with unresectable or metastatic melanoma attending Melanoma Institute Australia between June 2009 and January 2010.
 

  • The median overall survival (OS) from diagnosis of first distant metastasis in the complete cohort was 46.1 months for patients who are BRAF wild type (WT) and 11.1 months for BRAF-mutant patients (P=.006)3

  • In a separate study, a meta-analysis of 52 studies with a pooled population of 7519 patients, those patients with BRAF+ melanoma had a significantly higher risk of reduced OS (23%) vs patients with BRAF WT (hazard ratio, 1.23; 95% CI, 1.09-1.38)4

References: 1. Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep. 2012;14(5):449-457. 2. Barbour AP, Tang YH, Armour N, et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer. 2014;50(15):2668-2676.3. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246. 4. Ny L, Hernberg M, Nyakas M, et al. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. Acta Oncol. 2020;59(7):833-844.